Research ExplorerPublicationsHighlights der ASCO Jahrestagung 2018 zur Immuntherapie von ...

Highlights der ASCO Jahrestagung 2018 zur Immuntherapie von Kopf-Hals-Tumoren

Standard

Highlights der ASCO Jahrestagung 2018 zur Immuntherapie von Kopf-Hals-Tumoren. / Laban, S; Doescher, J; Busch, C-J; Wollenberg, B; Dietz, Andreas; Würdemann, N; Schuler, P J; Hoffmann, T K.

In: HNO, Vol. 66, No. 12, 12.2018, p. 880-887.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Laban, S, Doescher, J, Busch, C-J, Wollenberg, B, Dietz, A, Würdemann, N, Schuler, PJ & Hoffmann, TK 2018, 'Highlights der ASCO Jahrestagung 2018 zur Immuntherapie von Kopf-Hals-Tumoren', HNO, vol. 66, no. 12, pp. 880-887. https://doi.org/10.1007/s00106-018-0586-2

APA

Laban, S., Doescher, J., Busch, C-J., Wollenberg, B., Dietz, A., Würdemann, N., Schuler, P. J., & Hoffmann, T. K. (2018). Highlights der ASCO Jahrestagung 2018 zur Immuntherapie von Kopf-Hals-Tumoren. HNO, 66(12), 880-887. https://doi.org/10.1007/s00106-018-0586-2

Vancouver

Laban S, Doescher J, Busch C-J, Wollenberg B, Dietz A, Würdemann N et al. Highlights der ASCO Jahrestagung 2018 zur Immuntherapie von Kopf-Hals-Tumoren. HNO. 2018 Dec;66(12):880-887. https://doi.org/10.1007/s00106-018-0586-2

Bibtex

@article{3307d44bf6af49b39b9129b8df78fc97,
title = "Highlights der ASCO Jahrestagung 2018 zur Immuntherapie von Kopf-Hals-Tumoren",
abstract = "BACKGROUND: Immunotherapeutic strategies are becoming increasingly more important for head and neck cancer and numerous clinical trials were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2018.OBJECTIVE: In this review the most interesting clinical trials and trial results for immunotherapy of head and neck cancer are summarized.MATERIAL AND METHODS: All abstracts and presentations on immunotherapy of head and neck cancer at the annual meeting of the ASCO 2018 were screened to select the most interesting trials for a more detailed analysis.RESULTS: For head and neck cancer, practice changing phase III trial results were missing, but several noteworthy new strategies and trial results for immunotherapy were presented. Neoadjuvant immunotherapy trials, results concerning immunotherapy in old age, prognostic implications of immune-mediated adverse events and new immunotherapy combinations are summarized in this article.CONCLUSION: The role of immunotherapy for the treatment of head and neck cancer is markedly increasing. Many pioneering trials are currently ongoing, in the phase of data analysis or in planning.",
keywords = "Head and Neck Neoplasms/therapy, Humans, Immunologic Factors, Immunotherapy",
author = "S Laban and J Doescher and C-J Busch and B Wollenberg and Andreas Dietz and N W{\"u}rdemann and Schuler, {P J} and Hoffmann, {T K}",
year = "2018",
month = dec,
doi = "10.1007/s00106-018-0586-2",
language = "Deutsch",
volume = "66",
pages = "880--887",
journal = "HNO",
issn = "0017-6192",
publisher = "Springer",
number = "12",

}

RIS

TY - JOUR

T1 - Highlights der ASCO Jahrestagung 2018 zur Immuntherapie von Kopf-Hals-Tumoren

AU - Laban, S

AU - Doescher, J

AU - Busch, C-J

AU - Wollenberg, B

AU - Dietz, Andreas

AU - Würdemann, N

AU - Schuler, P J

AU - Hoffmann, T K

PY - 2018/12

Y1 - 2018/12

N2 - BACKGROUND: Immunotherapeutic strategies are becoming increasingly more important for head and neck cancer and numerous clinical trials were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2018.OBJECTIVE: In this review the most interesting clinical trials and trial results for immunotherapy of head and neck cancer are summarized.MATERIAL AND METHODS: All abstracts and presentations on immunotherapy of head and neck cancer at the annual meeting of the ASCO 2018 were screened to select the most interesting trials for a more detailed analysis.RESULTS: For head and neck cancer, practice changing phase III trial results were missing, but several noteworthy new strategies and trial results for immunotherapy were presented. Neoadjuvant immunotherapy trials, results concerning immunotherapy in old age, prognostic implications of immune-mediated adverse events and new immunotherapy combinations are summarized in this article.CONCLUSION: The role of immunotherapy for the treatment of head and neck cancer is markedly increasing. Many pioneering trials are currently ongoing, in the phase of data analysis or in planning.

AB - BACKGROUND: Immunotherapeutic strategies are becoming increasingly more important for head and neck cancer and numerous clinical trials were presented at the annual meeting of the American Society of Clinical Oncology (ASCO) 2018.OBJECTIVE: In this review the most interesting clinical trials and trial results for immunotherapy of head and neck cancer are summarized.MATERIAL AND METHODS: All abstracts and presentations on immunotherapy of head and neck cancer at the annual meeting of the ASCO 2018 were screened to select the most interesting trials for a more detailed analysis.RESULTS: For head and neck cancer, practice changing phase III trial results were missing, but several noteworthy new strategies and trial results for immunotherapy were presented. Neoadjuvant immunotherapy trials, results concerning immunotherapy in old age, prognostic implications of immune-mediated adverse events and new immunotherapy combinations are summarized in this article.CONCLUSION: The role of immunotherapy for the treatment of head and neck cancer is markedly increasing. Many pioneering trials are currently ongoing, in the phase of data analysis or in planning.

KW - Head and Neck Neoplasms/therapy

KW - Humans

KW - Immunologic Factors

KW - Immunotherapy

U2 - 10.1007/s00106-018-0586-2

DO - 10.1007/s00106-018-0586-2

M3 - SCORING: Review

C2 - 30402813

VL - 66

SP - 880

EP - 887

JO - HNO

JF - HNO

SN - 0017-6192

IS - 12

ER -